Cell-Permeable PI3Kγ Peptide for Selective PDE4D Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for fibroproliferative vascular diseases, such as intimal hyperplasia and restenosis, are limited by the non-selective inhibition of phosphodiesterases (PDEs) leading to systemic side effects and lack of isoform-specificity, and existing PI3Kγ inhibition strategies focus on catalytic activity without addressing its kinase-independent role in vascular smooth muscle cell (VSMC) proliferation.
Innovation Solution
A cell-permeable peptide targeting the N-terminal domain of PI3Kγ (KIT2014) disrupts the PI3Kγ/PKA interaction, specifically inhibiting PDE4D to elevate cAMP levels and reduce VSMC proliferation, thereby treating or preventing fibroproliferative vascular diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective PDE inhibitors are used to treat fibroproliferative vascular diseases, then VSMC proliferation is inhibited, but systemic side effects occur and isoform-specificity is lacking
Solution Approach 1:
The patent uses a cell-permeable peptide (KIT2014) as an intermediary that specifically targets and disrupts the PI3Kγ/PKA interaction complex. This peptide acts as a molecular mediator that selectively inhibits PDE4D enzyme activity without affecting other PDE isoforms, thereby achieving vascular-specific inhibition of VSMC proliferation while avoiding the systemic side effects associated with non-selective PDE inhibitors
Solution Approach 2:
The invention applies local quality by designing a peptide that specifically targets the N-terminal domain of PI3Kγ and the PKA binding interface. This localized intervention disrupts only the specific protein-protein interaction required for PDE4D activation in vascular smooth muscle cells, leaving other cellular processes and PDE isoforms unaffected, thus achieving selective therapeutic action
2Reliability
If existing PI3Kγ inhibition strategies targeting catalytic activity are used, then kinase function is inhibited, but kinase-independent role in VSMC proliferation is not addressed
Solution Approach 1:
The patent extracts and targets specifically the kinase-independent function of PI3Kγ by designing a peptide that binds to the N-terminal domain and disrupts the PI3Kγ/PKA protein-protein interaction. This approach separates the kinase-independent scaffolding function from the kinase catalytic activity, allowing selective inhibition of the latter while addressing the former through the peptide intervention
Solution Approach 2:
The invention segments the PI3Kγ protein function into two distinct targets: the kinase catalytic domain and the N-terminal domain involved in protein-protein interactions. By designing a peptide that specifically targets the N-terminal domain, the patent addresses the previously overlooked kinase-independent role of PI3Kγ in VSMC proliferation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide effectively reduces VSMC proliferation and intimal hyperplasia by selectively increasing cAMP levels, providing a targeted therapeutic approach without systemic side effects, suitable for conditions like restenosis, hypertension, and pulmonary arterial hypertension.
Implementation Method 1
A cell-permeable peptide targeting the N-terminal domain of PI3Kγ (KIT2014) disrupts the PI3Kγ/PKA interaction, specifically inhibiting PDE4D to elevate cAMP levels
Implementation Method 2
A cell-permeable peptide targeting the N-terminal domain of PI3Kγ (KIT2014) disrupts the PI3Kγ/PKA interaction
Data Source
Figure 1A~1E
Figure 2A~2C
Figure 3A~3D
AI summary
Fusion peptide, and pharmaceutical composition containing the same, for use in treating, preventing and/or delaying the onset of a fibroproliferative vascular disease, wherein the fusion peptide comprises: (a) an amino acid sequence as defined in SEQ ID No.: 1 or a related homolog having at least 85% similarity with SEQ ID No.: 1 and having the ability of the sequence SEQ ID No.: 1 to inhibit the kinase- independent function of PI3K, and (b) a peptide having the ability to penetrate a cell.